NTRA (natera.com) Enterprise Value-to-Revenue Coefficient

Public company logo of Natera Inc (NTRA)

Scaling DNA algorithms reduces costs for Natera, Inc. (NTRA), increasing the overall profitability of tests. The EV/Sales ratio visualizes the demand dynamics for assets, with the indicator currently standing at 14157.17. Recruiting leading bioinformaticians from academia strengthens the firm's position. Active hiring of geneticists ensures business expansion, while industry leadership guarantees the loyalty of key developers.

Natera Medical (NTRA): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Natera Corp (NTRA)

- current quotes and average value forecast:
- business market valuation indicators:
Fundamental company valuation:NTRA (natera.com)
Mass-produced product of Natera Inc

The EV/Sales metric determines the total enterprise value of the business, including debt, per unit of revenue, excluding the influence of capital structure. Natera, Inc. (NTRA) diversification into cancer diagnostics and reproductive testing directly impacts the company's enterprise value-to-sales ratio, reflecting the market's valuation of the scalability of these segments. Analyzing this trend allows for an objective assessment of the company's fundamental stability as it expands its customer base.